American Diabetes Association
Browse

Three-year follow-up after antiviral treatment in new-onset type 1 diabetes. Results from the Diabetes Virus Detection and Intervention trial.

Download (280.76 kB)
figure
posted on 2025-01-13, 18:03 authored by Ida M. Mynarek, Lars Krogvold, Freja B. Mørk, Trine W.H. Lawaetz, Trine Roald, Morten W. Fagerland, Nina Lindblom, Jacob Westman, Peter Barker, Heikki Hyöty, Johnny Ludvigsson, Kristian F. Hanssen, Jesper Johannesen, Knut Dahl-Jørgensen

Objective

In the Diabetes Virus Detection and Intervention trial, antiviral treatment with pleconaril and ribavirin was shown to decrease the decline in endogenous C-peptide one year after diagnosis of type 1 diabetes in children and adolescents compared to placebo. This paper reports the results two and three years after diagnosis.

Research Design and Methods

This was a multicenter, randomized, placebo controlled (1:1) trial of 96 newly diagnosed children and adolescents aged 6-15.9 years. Antiviral treatment (pleconaril and ribavirin) or placebo was given for six months from diagnosis, and participants were followed for three years. The primary outcome was residual C-peptide secretion, assessed by 2-h mixed-meal tolerance test, reported as the area under the curve (AUC). Secondary outcomes included insulin doses and hemoglobin A1c.

Results

At the three-year follow-up, 75 participants attended. At two years, the mean ± standard deviation AUC C-peptide in the placebo group was 0.27 ± 0.33 compared to 0.34 ± 0.37 in the pleconaril and ribavirin group. After three years, the AUC had decreased to 0.17 ± 0.23 and 0.25 ± 0.34 respectively. There was no statistically significant difference between the groups. The groups were also comparable with regard to secondary endpoints.

Conclusions

The decreased reduction in C-peptide levels after antiviral treatment is no longer present after two or three years. Further investigations are needed to explore options to use antiviral treatment in the prevention and treatment of type 1 diabetes.

Funding

The South-Eastern Norway Regional Health Authority, Norway (Grant number 2016119), Juvenile Diabetes Research Foundation, USA (Grant number 2-SRA-2019-810-M-B). European Union support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements 115797 (INNODIA) and 945268 (INNODIA HARVEST), supported by the European Union’s Horizon 2020 research and innovation program. All grants provided to Principal Investigator K.D-J. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC